title: Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.
abstract: Monkeypox virus (MPXV) infection has recently expanded in geographic distribution and can be fatal in up to 10% of cases. The intravenous (i.v.) inoculation of nonhuman primates (NHPs) results in an accelerated fulminant disease course compared to that of naturally occurring MPXV infection in humans. Alternative routes of inoculation are being investigated to define an NHP model of infection that more closely resembles natural disease progression. Our goal was to determine if the intrabronchial (i.b.) exposure of NHPs to MPXV results in a systemic disease that better resembles the progression of human MPXV infection. Here, we compared the disease course following an i.v. or i.b. inoculation of NHPs with 10-fold serial doses of MPXV Zaire. Classical pox-like disease was observed in NHPs administered a high virus dose by either route. Several key events were delayed in the highest doses tested of the i.b. model compared to the timing of the i.v. model, including the onset of fever, lesion appearance, peak viremia, viral shedding in nasal and oral swabs, peak cytokine levels, and time to reach endpoint criteria. Virus distribution across 19 tissues was largely unaffected by the inoculation route at the highest doses tested. The NHPs inoculated by the i.b. route developed a viral pneumonia that likely exacerbated disease progression. Based on the observations of the delayed onset of clinical and virological parameters and endpoint criteria that may more closely resemble those of human MPXV infection, the i.b. MPXV model should be considered for the further investigation of viral pathogenesis and countermeasures.
authors.affiliation: National Institutes of Health, NIAID/EVPS, Bethesda, MD 20892, USA. johnsonreed@mail.nih.gov
authors.forename: Reed F
authors.initials: RF
authors.lastname: Johnson
authors.forename: Julie
authors.initials: J
authors.lastname: Dyall
authors.forename: Dan R
authors.initials: DR
authors.lastname: Ragland
authors.forename: Louis
authors.initials: L
authors.lastname: Huzella
authors.forename: Russell
authors.initials: R
authors.lastname: Byrum
authors.forename: Catherine
authors.initials: C
authors.lastname: Jett
authors.forename: Marisa
authors.initials: M
authors.lastname: St Claire
authors.forename: Alvin L
authors.initials: AL
authors.lastname: Smith
authors.forename: Jason
authors.initials: J
authors.lastname: Paragas
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Blaney
authors.forename: Peter B
authors.initials: PB
authors.lastname: Jahrling
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D001980:Bronchi / Q000821:virology*; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D006801:Humans; D007275:Injections, Intravenous; D008252:Macaca fascicularis; D045908:Mpox, Monkeypox / Q000276:immunology / Q000635:transmission* / Q000821:virology*; D008993:Monkeypox virus / Q000235:genetics / Q000502:physiology*; D014709:Vero Cells; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral